類肉瘤病：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

市場概覽

• 預計到 2035 年，法國類肉瘤病市場規模將從約 2,200 萬美元成長到 5,500 萬美元，這表明市場將大幅擴張。
• 市場成長受以下因素支撐：
• 在慢性疾病的治療中，免疫抑制療法和生物製藥的使用日益增加。
• 診斷技術的改進和多器官病變長期監測的進步
• 市場規模的擴大是由治療週期延長和疑難雜症先進治療方法的日益普及所推動的。
• 未來的成長取決於標靶免疫調節療法的發展以及慢性進行性類肉瘤病管理策略的改進。

類肉瘤病概述

類肉瘤病是一種慢性多器官發炎性疾病，其特徵是遺傳易感個體免疫反應失調，導致受累器官形成非乾酪性肉芽腫。此病最常涉及肺和胸內淋巴結，但肺外病變也常發生於皮膚、眼、心臟、肝臟和神經系統。臨床表現多種多樣，從無症狀到慢性進行性性器官功能障礙，伴隨呼吸困難、持續咳嗽、疲倦、器官特異性併發症。

診斷需綜合觀察臨床表現、觀察及組織病理學檢查觀察。這包括影像學檢查觀察的雙側肺門淋巴結腫大以及經切片檢查證實的非乾酪性肉芽腫，並且必須排除感染性和惡性病因。對於有症狀的病例和病情進行性的患者，糖皮質激素仍是主要的治療手段，但胺基甲基葉酸和Azathioprine等免疫抑制劑常被用作替代荷爾蒙治療方案。對於難治性或重症病例，可能需要使用生物製藥治療，包括Infliximab等抗TNF製劑。

儘管部分患者病情可自發性緩解，但相當一部分患者會發展為慢性或進行性疾病，需要長期後續觀察和多學科管理。持續性疲勞、肺纖維化、心臟疾病和治療相關毒性仍然是尚未解決的重大臨床挑戰。治療前景日益聚焦於標靶免疫調節療法和長期疾病管理策略的改進。

主要亮點

• 在法國，預計到 2025 年，類肉瘤病病患者人數將約為 22,210 人，到 2035 年將增加至近 23,815 人，這反映出該疾病的負擔正在逐漸加重。
• 肺類肉瘤病仍然是主要的臨床表現，佔確診病例的大多數。
• 慢性進行性疾病和肺外病變仍是導致長期發生率的重要因素。
• 皮質類固醇仍然是標準治療方法，但由於長期使用類固醇的毒性，使用免疫抑制療法來節約類固醇的情況正在增加。
• 人們對生物目標療法的興趣日益濃厚，這為難治性和重症類肉瘤病病患者提供了更多治療選擇。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Sarcoidosis Market Outlook

Thelansis's "Sarcoidosis Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sarcoidosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Sarcoidosis Overview

Sarcoidosis is a chronic, multisystem inflammatory disorder characterized by the formation of non-caseating granulomas in affected organs, driven by dysregulated immune responses in genetically susceptible individuals. The disease most commonly affects the lungs and intrathoracic lymph nodes, although extrapulmonary involvement frequently occurs in the skin, eyes, heart, liver, and nervous system. Clinical presentation is highly variable, ranging from asymptomatic disease to chronic progressive organ dysfunction associated with dyspnoea, persistent cough, fatigue, and organ-specific complications.

Diagnosis is based on a combination of clinical, radiological, and histopathological findings, including imaging evidence of bilateral hilar lymphadenopathy and biopsy-confirmed non-caseating granulomas while excluding infectious and malignant causes. Corticosteroids remain the mainstay of therapy for symptomatic or progressive disease, while immunosuppressive agents such as methotrexate and azathioprine are commonly used as steroid-sparing therapies. Refractory or severe disease may require biologic therapies, including anti-TNF agents such as infliximab.

Despite spontaneous remission in some patients, a substantial proportion develop chronic or progressive disease requiring long-term monitoring and multidisciplinary management. Persistent fatigue, pulmonary fibrosis, cardiac involvement, and treatment-related toxicity continue to represent significant unmet clinical challenges. The evolving treatment landscape is increasingly focused on targeted immunomodulatory therapies and improved long-term disease management strategies.

Key Highlights

• In France, sarcoidosis prevalence cases are projected to increase from approximately 22,210 in 2025 to nearly 23,815 by 2035, reflecting a gradual increase in disease burden.
• Pulmonary sarcoidosis remains the predominant clinical presentation, accounting for the majority of diagnosed cases.
• Chronic progressive disease and extrapulmonary involvement continue to contribute significantly to long-term morbidity.
• Corticosteroids remain the standard of care; however, long-term steroid toxicity drives increasing use of steroid-sparing immunosuppressive therapies.
• Growing interest in targeted biologic therapies is expanding treatment options for refractory and severe sarcoidosis cases.

Market Overview

• The France sarcoidosis market is projected to grow from approximately $22 MN to $55 MN by 2035, reflecting notable market expansion.
• Market growth is supported by:
• Increasing use of immunosuppressive and biologic therapies in chronic disease management
• Improved diagnosis and long-term monitoring of multisystem disease involvement
• Market value growth is driven by prolonged treatment duration and increasing adoption of advanced therapies in refractory disease.
• Future growth will depend on development of targeted immunomodulatory therapies and improved management strategies for chronic progressive sarcoidosis.

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)